MAPT and Alzheimer disease: To date, four anti-tau antibodies (gosuranemab, tilavonemab, zagotenemab, and semorinemab) have failed to demonstrate a clear clinical benefit in patients with early AD, nor have they demonstrated any impact on tau pathology [93–97].